GKOS
Glaukos Corp · NYSE
- Sector Health Technology
- Industry Medical Specialties
- Website glaukos.com
- Employees(FY) 783
- ISIN US3773221029
Performance
-1.52%
1W
+6.05%
1M
+11.81%
3M
+28.83%
6M
+77.93%
YTD
+121.28%
1Y
Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
Technical Analysis of GKOS 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-12 19:00
GKOS: Raising target price to $121.00(Argus Research)
- 2024-11-08 07:00
- 2024-11-07 18:00
- 2024-11-07 06:18
- 2024-11-06 06:30
- 2024-11-06 06:02
Glaukos Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-11-05 19:00
GKOS: Lowering target price to $115.00(Argus Research)
- 2024-11-05 11:30
- 2024-11-05 11:18
Q3 2024 Glaukos Corp Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-05 09:56
- 2024-11-05 02:08
- 2024-11-04 17:25
- 2024-11-04 17:14
- 2024-11-04 16:25
Glaukos: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-04 16:05
Glaukos Announces Third Quarter 2024 Financial Results(Business Wire)
- 2024-11-04 03:05
Glaukos Announces Third Quarter 2024 Financial Results(Businesswire)
- 2024-10-31 21:01
- 2024-10-29 10:01
- 2024-10-28 10:01
- 2024-10-17 11:14
- 2024-10-17 10:06
Glaukos eyes FDA approval for ocular therapy after Phase III win(Pharmaceutical Technology)
- 2024-10-16 22:06
- 2024-10-16 17:36
- 2024-10-16 16:05
- 2024-10-16 04:05
- 2024-10-14 07:00
- 2024-10-14 06:25
- 2024-10-13 19:00
- 2024-10-09 07:00
- 2024-10-08 20:00
GKOS: Raising target price to $112.00(Argus Research)
Page 1 of 9
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.